Is Nexalin Technology Inc. (NXL) overvalued? · rev $301.6K
Nexalin Technology Inc. (NXL) is a medical devices company listed on NASDAQ.
This page asks whether Nexalin Technology Inc. (NXL) looks expensive on cached numbers — not a short thesis.
Latest reported NXL revenue for 2025-12-31 was $301.6K. Net income was -$8.2M. Revenue was up 78.8% from 2024-12-31 to 2025-12-31. NXL currently screens at market cap $8.5M.
NXL currently screens at market cap $8.5M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next NXL 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the NXL stock page for the full model, not this heading.
Not investment advice.